23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador’s Precision Medicines for Immunology & Inflammation
23andMe Holding Co. (Nasdaq: ME) and Mirador Therapeutics announced a strategic research collaboration focused on immunology and inflammation-related diseases. Mirador will utilize 23andMe's genetic and phenotypic database, the world's largest crowdsourced platform for genetic research, alongside their proprietary Mirador360™ development engine to advance target validation and precision medicine. The collaboration combines Mirador's extensive repository of immune-mediated disease data, including over two million human molecular profiles, with 23andMe's database, which has previously contributed to multiple drug discovery programs and two clinical stage assets in immuno-oncology.
23andMe Holding Co. (Nasdaq: ME) e Mirador Therapeutics hanno annunciato una collaborazione di ricerca strategica focalizzata su malattie immunologiche e infiammatorie. Mirador utilizzerà il database genetico e fenotipico di 23andMe, la piattaforma di ricerca genetica crowdsourced più grande del mondo, insieme al loro motore di sviluppo proprietario Mirador360™ per avanzare nella validazione degli obiettivi e nella medicina di precisione. La collaborazione combina l'ampio repository di dati sulle malattie mediate dal sistema immunitario di Mirador, che include oltre due milioni di profili molecolari umani, con il database di 23andMe, che ha già contribuito a numerosi programmi di scoperta di farmaci e a due asset in fase clinica nell'immuno-oncologia.
23andMe Holding Co. (Nasdaq: ME) y Mirador Therapeutics anunciaron una colaboración de investigación estratégica centrada en enfermedades relacionadas con la inmunología y la inflamación. Mirador utilizará la base de datos genética y fenotípica de 23andMe, la plataforma de investigación genética crowdsourced más grande del mundo, junto con su motor de desarrollo propietario Mirador360™ para avanzar en la validación de objetivos y en la medicina de precisión. La colaboración combina el amplio repositorio de datos sobre enfermedades mediadas por el sistema inmunológico de Mirador, que incluye más de dos millones de perfiles moleculares humanos, con la base de datos de 23andMe, que anteriormente ha contribuido a múltiples programas de descubrimiento de fármacos y a dos activos en etapa clínica en inmuno-oncología.
23andMe 홀딩 컴퍼니 (Nasdaq: ME)와 미라도르 테라퓨틱스는 면역학 및 염증 관련 질병에 중점을 둔 전략적 연구 협력을 발표했습니다. 미라도르는 23andMe의 세계 최대의 크라우드소스 유전 연구 플랫폼인 유전자 및 표현형 데이터베이스를 활용하여 그들의 독자적인 Mirador360™ 개발 엔진과 함께 목표 검증 및 정밀 의학을 발전시키기 위해 노력할 것입니다. 이 협력은 미라도르의 면역 매개 질병 데이터 방대한 저장소, 즉 200만 개 이상의 인간 분자 프로필과 함께 23andMe의 데이터베이스를 결합하여 면역 항암 치료에 있어 다수의 의약품 발견 프로그램 및 두 개의 임상 단계 자산에 기여했습니다.
23andMe Holding Co. (Nasdaq: ME) et Mirador Therapeutics ont annoncé une collaboration de recherche stratégique axée sur l'immunologie et les maladies liées à l'inflammation. Mirador utilisera la base de données génétiques et phénotypiques de 23andMe, la plus grande plateforme de recherche génétique participative au monde, ainsi que leur moteur de développement propriétaire Mirador360™ pour faire progresser la validation des cibles et la médecine personnalisée. Cette collaboration associe le vaste répertoire de données de Mirador sur les maladies médiées par le système immunitaire, comprenant plus de deux millions de profils moléculaires humains, à la base de données de 23andMe, qui a déjà contribué à plusieurs programmes de découverte de médicaments et à deux actifs en phase clinique en immuno-oncologie.
23andMe Holding Co. (Nasdaq: ME) und Mirador Therapeutics haben eine strategische Forschungszusammenarbeit bekannt gegeben, die sich auf immunologische und entzündungsbedingte Krankheiten konzentriert. Mirador wird die genetische und phänotypische Datenbank von 23andMe nutzen, die größte crowdsourced Plattform für genetische Forschung weltweit, zusammen mit ihrer proprietären Mirador360™ Entwicklungsmaschine, um die Zielvalidierung und personalisierte Medizin voranzutreiben. Die Zusammenarbeit kombiniert Miradors umfangreiches Repository an Daten zu immunvermittelten Krankheiten, einschließlich über zwei Millionen menschlichen molekularen Profilen, mit der Datenbank von 23andMe, die bereits zu mehreren Programmen zur Arzneimittelforschung und zu zwei klinischen Asset-Entwicklungen in der Immunonkologie beigetragen hat.
- Strategic partnership leverages world's largest genetic research database for drug development
- Access to over 2 million human molecular profiles through Mirador360™
- Previous successful track record with multiple drug discovery programs and two clinical stage assets
- None.
Insights
This strategic collaboration marks a significant step in precision medicine for immunology and inflammation (I&I). The partnership leverages 23andMe's vast genetic database - the world's largest crowdsourced platform for genetic research - with Mirador's Mirador360™ development engine. The combination of these resources creates a powerful platform for drug discovery and development.
The deal's value lies in accelerating target validation and precision medicine development. Mirador's existing repository of over two million human molecular profiles combined with 23andMe's genetic and phenotypic data significantly enhances their drug development capabilities. Previous collaborations using 23andMe's database have already yielded multiple drug discovery programs and two clinical-stage assets in immuno-oncology.
For 23andMe, this represents a strategic move to monetize their database while maintaining strict privacy controls. While financial terms weren't disclosed, such partnerships typically involve milestone payments and potential royalties, providing future revenue opportunities.
SUNNYVALE, Calif. and SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and preventive health company, and Mirador Therapeutics, a next-generation precision medicine company focused on developing first-in-class or best-in-class therapeutics for immunology and inflammation (I&I)-related diseases, today announced a strategic research collaboration. Under the agreement, Mirador will leverage a targeted set of aggregated, de-identified genetic and phenotypic data from the 23andMe research database and its proprietary Mirador360™ development engine to enable target validation and precision medicine.
The 23andMe genetic and phenotypic health information database is the world’s largest crowdsourced platform for genetic research. Insights gleaned from the 23andMe database have resulted in previous pharma collaborations that have generated multiple drug discovery programs, as well as two clinical stage assets in immuno-oncology, and more than 300 scientific publications. Mirador will use the 23andMe database to augment its proprietary Mirador360™ development engine, which already houses one of the most extensive repositories of immune-mediated disease data, including over two million human molecular profiles.
“Our new partnership with 23andMe supercharges the Mirador mission to rapidly advance transformational precision therapies for patients living with chronic immune-mediated inflammatory and fibrotic diseases,” said Mark C. McKenna, Chairman and CEO of Mirador. “Combining Mirador360’s cutting-edge biology, multi-modal data and AI capabilities with the unparalleled genetic and phenotypic insights from the 23andMe database will enable us to accelerate our progress toward solving major unmet needs in I&I.”
“Mirador is a pioneer in I&I precision medicine, and our collaboration harnesses the power of 23andMe’s data and research platform to identify new targets and develop promising new drugs,” said Anne Wojcicki, CEO and Co-Founder of 23andMe. “We hope this can ultimately help the millions of patients living with a range of I&I diseases who urgently need treatment options.”
Protecting participant privacy
23andMe has strong privacy protections in place, and customers are in control of their data. Customers have the option to consent to participate in the 23andMe Research program, which is overseen by a third party Institutional Review Board (IRB) to ensure research being conducted meets the highest ethical standards. Only data from consented research participants is used for 23andMe research, and for those that choose to opt-in, their information is de-identified for research activities, meaning participants’ personally identifiable information such as name, age, sex and contact information is stripped from their genetic information, with the two sets of data stored separately. If a customer originally opted-in to participate in 23andMe’s Research program, they can easily withdraw at any time.
About 23andMe
23andMe is a genetics-led consumer healthcare and therapeutics company empowering a healthier future. For more information, please visit www.23andme.com.
About Mirador Therapeutics
Mirador is a next-generation precision medicine company focused on developing first-in-class or best-in-class precision medicines for immunology and inflammation. Mirador aims to revolutionize precision medicine with its proprietary Mirador360™ development engine that leverages cutting-edge biology, multi-modal data and advanced analytics to rapidly advance new medicines for patients living with chronic immune-mediated inflammatory and fibrotic diseases. Launched in 2024, Mirador has raised over
Contact Information
23andMe
Media: press@23andMe.com
Investor Relations: investors@23andMe.com
Mirador
Media: dan@1abmedia.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including. All statements, other than statements of historical fact, included or incorporated in this press release are forward-looking statements. The words "believes," "anticipates," "estimates," "plans," "expects," "intends," "may," "could," "should," "potential," "likely," "projects," “predicts,” "continue," "will," “schedule,” and "would" or, in each case, their negative or other variations or comparable terminology, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on 23andMe’s current expectations and projections about future events and various assumptions. 23andMe cannot guarantee that it will actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements and you should not place undue reliance on 23andMe’s forward-looking statements. These forward-looking statements involve a number of risks, uncertainties (many of which are beyond the control of 23andMe), or other assumptions that may cause actual results or performance to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission, and as revised and updated by our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The statements made herein are made as of the date of this press release and, except as may be required by law, 23andMe undertakes no obligation to update them, whether as a result of new information, developments, or otherwise.
FAQ
What is the purpose of 23andMe's collaboration with Mirador Therapeutics?
How many molecular profiles does Mirador360™ have access to in their database?
What has 23andMe's (ME) genetic database previously achieved in drug development?
